Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter

Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01270152

Enrollment

Registered

2011-01-05

Start date

2008-10-31

Completion date

2010-07-31

Last updated

2011-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Occluded Totally Implanted Central Venous Catheter

Keywords

ascorbic acid, catheterization central venous, nursing care

Brief summary

The hypothesis of the study is to evaluate whether ascorbic acid is able to clear totally implanted central venous catheter

Detailed description

Totally implanted catheter is often occluded and thrombolytic drugs are usually used to restore permeability. In Brazil, the ascorbic acid has been used successfully by a service specialist in cancer treatment. However, no literature on international research that evaluates the efficacy and safety of this procedure. That was why it was decided to develop this research.

Interventions

DRUGAscorbic Acid

comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of partial or complete obstruction of the totally implanted central venous catheter; * No signs of inflammation in the area of the port.

Exclusion criteria

* Use of oral anticoagulants or intravenous administration in the last seven days; * Diagnostic and / or suspected infection in the totally implanted central venous catheter; * Rupture, displacement or fissure of the totally implanted central venous catheter; * Presence of thrombosis in the vein where the catheter is inserted.

Design outcomes

Primary

Measure	Time frame	Description
Restore patency	60 minutes after administration of ascorbic acid	the ascorbic acid is administered and remains inside the catheter within 60 minutes. The recovery of permeability is checked every 15 minutes until the maximum of 60 minutes

Secondary

Measure	Time frame	Description
Eosinophil count	within 24 hours	the count of eosinophils was determined by collecting blood sample immediately prior to administration of ascorbic acid and 24 hours after

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026